MGCD265 is our clinical candidate for our multi-targeted (c-MET) kinase program. MGCD265 targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Ron and Tie-2 receptor tyrosine kinases, which appear to play key roles in tumor development and blood vessel formation (angiogenesis) and tumor survival.

The c-MET target has become one of intense scientific and pharmaceutical interest because of its direct involvement in tumor cell survival and angiogenesis. In addition, there is strong evidence that c-MET levels are associated with poor prognosis in several major solid tumor types.

MGCD265 is currently in two Phase I single-agent clinical trials for solid tumor cancers (Trials 101 and 102) and in a Phase II program (Trial 103) for solid tumors and NSCLC and will be administered in combination with either Tarceva(R) or docetaxel.